פלוניקסין תמיסה להזרקה קומקס וטרינרי ישראל - עברית - Ministry of Health

פלוניקסין תמיסה להזרקה קומקס וטרינרי

comex ltd - flunixin as meglumine - תמיסה להזרקה - flunixin as meglumine 50 mg/ml

יוקריאס 50/850 מ"ג ישראל - עברית - Ministry of Health

יוקריאס 50/850 מ"ג

novartis pharma services ag - metformin hydrochloride 850 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus:• eucreas is indicated in the treatment of type 2 diabetes patients who are unable to achieve sufficient glycemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.• eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea.• eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

יוקריאס 50/500 מ"ג ישראל - עברית - Ministry of Health

יוקריאס 50/500 מ"ג

novartis pharma services ag - metformin hydrochloride 500 mg; vildagliptin 50 mg - film coated tablets - metformin - eucreas is indicated in the treatment of type 2 diabetes mellitus patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.

קומפטקט 15 מג  850 מג ישראל - עברית - Ministry of Health

קומפטקט 15 מג 850 מג

tzamal bio-pharma ltd - metformin hydrochloride; pioglitazone as hydrochloride - טבליות מצופות פילם - metformin hydrochloride 850 mg; pioglitazone as hydrochloride 15 mg - metformin - metformin - competact is indicated as second line treatment of type 2 diabetes mellitus adult patients,particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.after initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in hba1c). in patients who fail to show an adequate response, pioglitazone should be discontinued. in light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained.

אבנדמט 4 מ"ג/1000 מ"ג ישראל - עברית - Ministry of Health

אבנדמט 4 מ"ג/1000 מ"ג

glaxo smith kline (israel) ltd - metformin hydrochloride 1000 mg; rosiglitazone as maleate 4 mg - tablets - metformin and rosiglitazone - avandamet is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus : as dual combination therapy in patients who are already treated with combination rosiglitazone and metformin or who are not adequately controlled on metformin alone or in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea.

ביידוריון 2 מג ישראל - עברית - Ministry of Health

ביידוריון 2 מג

astrazeneca (israel) ltd - exenatide - אבקה וממס להכנת תרחיף להזרקה - exenatide 2 mg - exenatide - exenatide - bydureon is indicated for treatment of type 2 diabetes mellitus in combination with : • metformin• sulphonylurea• metformin and sulphonylureain adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

ויקטוזה ישראל - עברית - Ministry of Health

ויקטוזה

novo nordisk ltd., israel - liraglutide - תמיסה להזרקה - liraglutide 6.0 mg/ml - liraglutide - liraglutide - for the treatment of adults with type 2 diabetes mellitus to achieve glycemic control : in combination with : - metformin or a sulphonylurea, in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with mentformin or sulphonylurea. - metformin and sulphonylurea or metformin and a thiazolidinedione in patients with insufficient glycemic control despite dual therapy.

אמיודקור זריקות ישראל - עברית - Ministry of Health

אמיודקור זריקות

sanofi israel ltd - amiodarone hydrochloride - תמיסה להזרקה - amiodarone hydrochloride 50 mg / 1 ml - amiodarone - amiodarone - corronary insufficiency, arrhythmias resistant to other treatments, wolf parkinson white syndrome.

קרבדקסון 6.25 ישראל - עברית - Ministry of Health

קרבדקסון 6.25

dexcel ltd, israel - carvedilol - טבליה - carvedilol 6.25 mg - carvedilol - carvedilol - treatment of symptomatic congestive heart failure. carvedexxon may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ace inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.

קרבדקסון 12.5 ישראל - עברית - Ministry of Health

קרבדקסון 12.5

dexcel ltd, israel - carvedilol - טבליה - carvedilol 12.5 mg - carvedilol - carvedilol - treatment of symptomatic congestive heart failure. carvedexxon may be used as adjunct to standard therapy, but may also be used in those patients unable to tolerate an ace inhibitor, or those who are not receiving digitalis, hydralazine or nitrate therapy.